Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;30(Suppl 4):S913-S946.
doi: 10.5152/tjg.2019.061119.

2019 Expert opinion on biological treatment use in inflammatory bowel disease management

Murat Törüner  1 , Hale Akpınar  2 , Filiz Akyüz  3 , Ülkü Dağlı  4 , Hülya Över Hamzaoğlu  5 , Ahmet Tezel  6 , Belkıs Ünsal  7 , Süleyman Yıldırım  8 , Aykut Ferhat Çelik  8
Affiliations

2019 Expert opinion on biological treatment use in inflammatory bowel disease management

Murat Törüner et al. Turk J Gastroenterol. 2019 Nov.
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: The authors have no conflict of interest to declare.

Figures

Figure 1
Figure 1
Thiopurine pharmacology
Figure 2
Figure 2
Molecules targeting IL-12/IL-23 axis in IBD (148).
Figure 3
Figure 3
The JAK-STAT signaling pathway. JAK inhibitors are new therapeutic agents which are currently being investigated in clinical trials in IBD. First-generation JAK inhibitors (e.g., tofacitinib) target multiple JAKs, whereas second-generation JAK inhibitors (e.g., filgotinib) selectively target one JAK (161).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Marshall JK, Irvine EJ. Rectal corticosteroids versus alternative treatments in ulcerative colitis: A meta-analysis. Gut. 1997;40:775–81. doi: 10.1136/gut.40.6.775. - DOI - PMC - PubMed
    1. Mulder CJ, Fockens P, Meijer JW, von der Heide H, Wiltink EH, Tytgat GN. Beclomethasone dipropionate (3mg) versus 5-aminosalicylic acid (2g) versus the combination of both (3mg/2g) as retention enemas in active ulcerative proctitis. Eur J Gastroenterol Hepatol. 1996;8:549–53. doi: 10.1097/00042737-199606000-00010. - DOI - PubMed
    1. Gionchetti P, Rizello F, Venturi A, et al. Comparison of mesalazine suppositories in proctitis and distal proctosigmoiditis. Aliment Pharmacol Ther. 1997;11:1053–7. doi: 10.1046/j.1365-2036.1997.00259.x. - DOI - PubMed
    1. Watanabe M, Nishino H, Sameshima Y, Ota A, Nakamura S, Hibi T. Randomised clinical trial: evaluation of the eficacy of mesalasine (mesalamine) suppositories in patients with ulcerative colitis and active rectal inflammation- a placebo-controlled study. Aliment Pharmacol Ther. 2013;38:264–73. doi: 10.1111/apt.12362. - DOI - PubMed
    1. Gionchetti P, Rizello F, Venturi A, et al. Comparison of oral versus rectal mesalazine in the treatment of ulcerative proctitis. Dis Colon Rectum. 1998;41:93–7. doi: 10.1007/BF02236902. - DOI - PubMed

MeSH terms

Substances